The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.
Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on th...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0311755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849228153862488064 |
|---|---|
| author | Mohammed Yousef Almulhim |
| author_facet | Mohammed Yousef Almulhim |
| author_sort | Mohammed Yousef Almulhim |
| collection | DOAJ |
| description | Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on the efficacy of novel biomarkers for AKI detection and management. Database searches yielded 17 relevant studies which were critically appraised. Key themes were biomarker efficacy in predicting AKI risk and severity before functional changes; potential to improve clinical management through earlier diagnosis, prognostic enrichment, and guiding interventions; emerging roles as therapeutic targets and prognostic tools; and ongoing challenges requiring further validation. Overall, novel biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cell cycle arrest markers ([TIMP-2] •[IGFBP7]) demonstrate capability for very early AKI prediction and accurate risk stratification. Their incorporation has potential to facilitate timely targeted interventions and personalized management. However, factors influencing biomarker performance, optimal cutoffs, cost-effectiveness, and impact on patient outcomes require robust validation across diverse settings before widespread implementation. Addressing these limitations through ongoing research can help translate novel biomarkers into improved detection, prognosis, and management of AKI in clinical practice. |
| format | Article |
| id | doaj-art-5dacc831a8be4987b181ca935dc46996 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5dacc831a8be4987b181ca935dc469962025-08-23T05:32:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031175510.1371/journal.pone.0311755The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.Mohammed Yousef AlmulhimAcute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on the efficacy of novel biomarkers for AKI detection and management. Database searches yielded 17 relevant studies which were critically appraised. Key themes were biomarker efficacy in predicting AKI risk and severity before functional changes; potential to improve clinical management through earlier diagnosis, prognostic enrichment, and guiding interventions; emerging roles as therapeutic targets and prognostic tools; and ongoing challenges requiring further validation. Overall, novel biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cell cycle arrest markers ([TIMP-2] •[IGFBP7]) demonstrate capability for very early AKI prediction and accurate risk stratification. Their incorporation has potential to facilitate timely targeted interventions and personalized management. However, factors influencing biomarker performance, optimal cutoffs, cost-effectiveness, and impact on patient outcomes require robust validation across diverse settings before widespread implementation. Addressing these limitations through ongoing research can help translate novel biomarkers into improved detection, prognosis, and management of AKI in clinical practice.https://doi.org/10.1371/journal.pone.0311755 |
| spellingShingle | Mohammed Yousef Almulhim The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. PLoS ONE |
| title | The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. |
| title_full | The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. |
| title_fullStr | The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. |
| title_full_unstemmed | The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. |
| title_short | The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. |
| title_sort | efficacy of novel biomarkers for the early detection and management of acute kidney injury a systematic review |
| url | https://doi.org/10.1371/journal.pone.0311755 |
| work_keys_str_mv | AT mohammedyousefalmulhim theefficacyofnovelbiomarkersfortheearlydetectionandmanagementofacutekidneyinjuryasystematicreview AT mohammedyousefalmulhim efficacyofnovelbiomarkersfortheearlydetectionandmanagementofacutekidneyinjuryasystematicreview |